[go: up one dir, main page]

PE20060424A1 - Polimorfos de 4-[[(7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil]amino]-3-metoxi-n-(1-metil-4-piperidinil) benzamida como inhibidores de quinasa - Google Patents

Polimorfos de 4-[[(7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil]amino]-3-metoxi-n-(1-metil-4-piperidinil) benzamida como inhibidores de quinasa

Info

Publication number
PE20060424A1
PE20060424A1 PE2005000934A PE2005000934A PE20060424A1 PE 20060424 A1 PE20060424 A1 PE 20060424A1 PE 2005000934 A PE2005000934 A PE 2005000934A PE 2005000934 A PE2005000934 A PE 2005000934A PE 20060424 A1 PE20060424 A1 PE 20060424A1
Authority
PE
Peru
Prior art keywords
methyl
cyclopentil
pteridinyl
benzamide
piperidinyl
Prior art date
Application number
PE2005000934A
Other languages
English (en)
Inventor
Guenter Linz
Peter Sieger
Rolf Herter
Werner Rall
Rolf Schmid
Matthias Hoffmann
Gerd F Kraemer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060424(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20060424A1 publication Critical patent/PE20060424A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A UN COMPUESTO 4-[[(7R)-8-CICLOPENTIL-7-ETIL-5,6,7,8-TETRAHIDRO-5-METIL-6-OXO-2-PTERIDINIL]AMINO]-3-METOXI-N-(1-METIL-4-PIPERIDINIL)BENZAMIDA, EN SU FORMA DE MONOHIDRATO, TRIHIDRATO, ANHIDRIDO. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA DE ADMINISTRACION ORAL, ENTERICA, INTRAVENOSA, PERITONEAL, O INYECCION Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA TIPO POLO, UTILES EN EL TRATAMIENTO DE CANCER, ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES
PE2005000934A 2004-08-14 2005-08-12 Polimorfos de 4-[[(7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil]amino]-3-metoxi-n-(1-metil-4-piperidinil) benzamida como inhibidores de quinasa PE20060424A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04019366 2004-08-14

Publications (1)

Publication Number Publication Date
PE20060424A1 true PE20060424A1 (es) 2006-06-09

Family

ID=35311878

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000934A PE20060424A1 (es) 2004-08-14 2005-08-12 Polimorfos de 4-[[(7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil]amino]-3-metoxi-n-(1-metil-4-piperidinil) benzamida como inhibidores de quinasa

Country Status (19)

Country Link
US (3) US7728134B2 (es)
EP (1) EP1778691A1 (es)
JP (1) JP2008509953A (es)
KR (1) KR101221864B1 (es)
CN (1) CN101006090A (es)
AR (1) AR052404A1 (es)
AU (1) AU2005274340B2 (es)
BR (1) BRPI0514351A2 (es)
CA (1) CA2578098A1 (es)
EA (1) EA011407B1 (es)
EC (1) ECSP077249A (es)
IL (1) IL181302A0 (es)
MX (1) MX2007001854A (es)
NO (1) NO20070752L (es)
NZ (1) NZ553649A (es)
PE (1) PE20060424A1 (es)
TW (1) TWI370131B (es)
UA (1) UA87865C2 (es)
WO (1) WO2006018222A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20040219338A1 (en) * 2003-05-01 2004-11-04 Hebrink Timothy J. Materials, configurations, and methods for reducing warpage in optical films
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008009909A1 (en) * 2006-07-17 2008-01-24 Astrazeneca Ab Pteridimones as modulators of polo-like kinase
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008076392A2 (en) 2006-12-14 2008-06-26 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
CA2695406A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
US8461149B2 (en) * 2007-08-15 2013-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
CA2728729C (en) * 2008-06-23 2016-09-27 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
SG181908A1 (en) * 2009-12-23 2012-08-30 Elan Pharm Inc Pteridinones as inhibitors of polo-like kinase
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
JP2017512186A (ja) * 2014-01-31 2017-05-18 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジヒドロプテリジノン誘導体およびその使用
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
JP2017526741A (ja) 2014-08-08 2017-09-14 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体およびその使用
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
HK1256419A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
CA2996974A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CN108472295B (zh) 2015-11-25 2022-04-15 达纳-法伯癌症研究所股份有限公司 二价溴结构域抑制剂及其用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8303657A (nl) 1983-10-24 1985-05-17 Pharmachemie Bv Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan.
DE3537761A1 (de) 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
FR2645152B1 (fr) 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
US5043270A (en) 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
CA2029651C (en) 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (es) 1992-09-26 1996-04-21 Hoechst Ag
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
GB9418499D0 (en) * 1994-09-14 1994-11-02 Ciba Geigy Ag Process for producing n-methylated organic pigments
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
DK0825979T3 (da) 1995-05-19 2001-05-07 Novartis Ag Fremgangsmåde til fremstilling af aromatiske nitroforbindelser
US5698556A (en) 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
JP3887836B2 (ja) * 1995-12-21 2007-02-28 東ソー株式会社 Ｎ−メチルイミダゾール類の製造法
RS49597B (sr) 1996-09-23 2007-06-04 Eli Lilly And Company, Olanzapin dihidrat d
CN1312810A (zh) 1998-08-11 2001-09-12 辉瑞产品公司 作为磷酸二酯酶4抑制剂的取代1,8－二氮杂萘－4(1h)－酮类化合物
CZ2002846A3 (cs) 1999-09-15 2003-02-12 Warner-Lambert Company Pteridinony, jako inhibitory kinasy
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
CN1422268A (zh) 2000-03-06 2003-06-04 沃尼尔·朗伯公司 5－烷基吡啶并[2,3－d]嘧啶酪氨酸激酶抑制剂
DE10018783A1 (de) 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10058119A1 (de) 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
KR100955589B1 (ko) * 2001-09-04 2010-04-30 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 신규한 디하이드로프테리디논, 이의 제조방법 및 이를 함유하는 약제학적 조성물
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
IL162506A0 (en) 2001-12-14 2005-11-20 Applied Research Systems Ovulation induction
CN1649853A (zh) 2002-05-03 2005-08-03 舍林股份公司 噻唑烷酮类化合物、其制备方法以及作为药物的应用
FR2843114B1 (fr) * 2002-08-01 2004-09-10 Poudres & Explosifs Ste Nale Procede de monomethylation d'heterocycles azotes
BR0313160A (pt) 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BR0318145A (pt) 2003-02-26 2006-02-21 Boehringer Ingelheim Pharma dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
CN1764474B (zh) 2003-03-26 2011-02-02 惠氏公司 免疫原性组合物及方法
EP1617820B1 (en) 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
DE102004002557A1 (de) 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
WO2005067935A1 (de) 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
DE102004034623A1 (de) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1786817A1 (de) 2004-08-26 2007-05-23 Boehringer Ingelheim International GmbH Pteridinone als plk (polo like kinase) inhibitoren
WO2006021548A1 (de) 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
JP2009503014A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療におけるジヒドロプテリジノン
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
JP2009529038A (ja) * 2006-03-07 2009-08-13 アストラゼネカ・アクチエボラーグ ピペリジン誘導体、それらの製造法、治療剤としてのそれらの使用およびそれらを含む医薬組成物
CA2695406A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative

Also Published As

Publication number Publication date
EA011407B1 (ru) 2009-02-27
US8202867B2 (en) 2012-06-19
KR101221864B1 (ko) 2013-01-14
JP2008509953A (ja) 2008-04-03
NZ553649A (en) 2010-11-26
UA87865C2 (en) 2009-08-25
US20060035902A1 (en) 2006-02-16
EP1778691A1 (de) 2007-05-02
BRPI0514351A2 (pt) 2012-10-30
US20090298840A1 (en) 2009-12-03
EA200700387A1 (ru) 2007-08-31
US7728134B2 (en) 2010-06-01
AR052404A1 (es) 2007-03-21
TWI370131B (en) 2012-08-11
IL181302A0 (en) 2007-07-04
CN101006090A (zh) 2007-07-25
TW200619220A (en) 2006-06-16
WO2006018222A8 (de) 2006-06-15
US20090318457A1 (en) 2009-12-24
NO20070752L (no) 2007-05-10
KR20070050967A (ko) 2007-05-16
CA2578098A1 (en) 2006-02-23
ECSP077249A (es) 2007-03-29
WO2006018222A1 (de) 2006-02-23
AU2005274340B2 (en) 2012-04-05
US8034816B2 (en) 2011-10-11
AU2005274340A1 (en) 2006-02-23
MX2007001854A (es) 2007-03-28

Similar Documents

Publication Publication Date Title
PE20060424A1 (es) Polimorfos de 4-[[(7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil]amino]-3-metoxi-n-(1-metil-4-piperidinil) benzamida como inhibidores de quinasa
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
TW200626558A (en) Indazolone derivatives
SG149033A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
TW200615266A (en) Organic compounds
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MX2010005824A (es) Derivados de aminotiazol.
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
EA201101507A1 (ru) Способы лечения солидных опухолей
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
BRPI0513843A (pt) composto ou um sal ou solvato ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, forma de dosagem, uso de um composto, e, sal de cloridrato
WO2006086447A3 (en) Pyridazine derivatives and their use as therapeutic agents
BR0314612A (pt) Composição farmacêutica estabilizada, contendo excipientes básicos
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
NZ596739A (en) Methods of treating proliferative diseases
TW200716628A (en) Novel compounds
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
EA201001344A1 (ru) Азотсодержащие бициклические соединения, активные при состояниях хронической боли

Legal Events

Date Code Title Description
FC Refusal